FDA Proposes Updates to Patent Listing Requirements for New Drug Applications

Summary

The Food and Drug Administration (FDA) is proposing to update its patent listing requirements for new drug applications (NDAs) to ensure that applicants list only relevant patents and to streamline the approval process for abbreviated new drug applications (ANDAs) and 505(b)(2) applications. The proposal aims to make the patent listing process more efficient and to enhance the review process for these applications.